CDT Equity CDT

CDT Equity Inc. is a data driven pharmaceutical development company that focuses on identifying enhancing and advancing high potential therapeutic assets through scientific innovation and strategic partnerships.
The company evolved from Conduit Pharmaceuticals Inc. and now leverages artificial intelligence solid form chemistry and efficient asset repositioning to accelerate the development of novel treatments.
Its strategy centers on unlocking the untapped value of clinical stage compounds especially those deprioritized by larger pharmaceutical companies that have strong Phase I safety data.
Through advanced co crystallization and solid form technologies developed at its Cambridge facilities the company improves drug properties and extends patent life by up to 20 years.
In partnership with Sarborg Limited it applies AI powered signature analysis to rapidly identify new therapeutic applications and combinations for existing compounds.
The pipeline includes candidates such as the AZD1656 glucokinase activator its metabolite AZD5658 and the myeloperoxidase inhibitor AZD5904 which are being evaluated for autoimmune disorders idiopathic male infertility oncology dermatology rare disease and animal health.
Ongoing in vitro and in vivo studies guided by AI insights are designed to support licensing and commercialization partnerships.
The company intends to seek an exit through third party license deals following successful pre clinical trials entering into agreements with third parties to pursue further development FDA approval commercialization and marketing of its assets.

The company generates revenue primarily by licensing its clinical assets to third parties after completing pre clinical validation.
It expects to receive up front milestone payments and ongoing royalty income for the life of the asset patent when a licensee advances the asset through clinical development approval and commercialization.
The licensing model allows CDT Equity Inc. to avoid the high costs of conducting late stage clinical trials while still capturing financial upside from successful assets.
In addition to out licensing the company may earn income from service agreements but its core financial strategy relies on the proceeds from licensing deals with larger pharma or biotech firms.
The company has secured rights to develop AZD1656 AZD5658 and AZD5904 under a license agreement with AstraZeneca which provides a foundation for future revenue generating partnerships.
It also collaborates with Manoira to explore veterinary applications although that arrangement is royalty free and intended to generate data for its human programs.
The firm anticipates that any future royalty streams will be reinvested into the pipeline to support the discovery and development of additional high potential assets.

CDT Equity Inc. operates in a highly competitive pharmaceutical and biotechnology industry where rivals include large multinational pharma companies mid sized biotech firms academic research institutions and government laboratories.
The company differentiates itself by focusing on assets that larger firms have deprioritized leveraging its AI driven disease mapping and solid form chemistry capabilities to enhance drug properties and extend patent life.
Its lean asset agnostic model enables rapid adaptation and capital efficiency while avoiding the overhead of owning manufacturing facilities.
Partnerships with Sarborg for predictive analytics and with Manoira for animal health applications broaden its technological reach and provide additional data streams.
The firm maintains a growing intellectual property portfolio with multiple pending patent applications in jurisdictions such as the United States Europe China Japan and others which strengthens its defensive position.
By concentrating on early stage assets with strong safety data and applying innovative solid form and AI techniques CDT Equity Inc. aims to deliver high leverage development outcomes that are difficult for traditional competitors to replicate.

The company serves pharmaceutical and biotechnology enterprises that seek novel therapeutic candidates for further development and eventual commercialization.
While specific customer names are not disclosed in the filing its licensing partners are expected to include major drug makers that wish to expand their pipelines with differentiated assets.
The relationship with AstraZeneca as the licensor of AZD1656 AZD5658 and AZD5904 demonstrates the type of collaboration that can evolve into a revenue generating licensee arrangement.
The collaboration with Manoira to explore veterinary applications indicates a customer base that extends to animal health companies interested in novel compounds for the veterinary market.
CDT Equity Inc. intends to enter into licensing agreements with third parties following successful pre clinical trials thereby converting its pipeline assets into revenue streams from established pharma and biotech partners.